Evidence-based insight on pain therapeutics and trials
ClinicalTrials.gov entries contain more honest information than most press releases, but only for readers who know where to look. This field guide walks through eligibility criteria, endpoint language, and stopping rules using a real NGF-inhibitor trial as a worked example.
Analgesic trials can succeed or fail on the strength of dose selection, titration schedules, and rescue-medication rules rather than the drug's underlying biology. This analysis examines how dosing decisions shaped divergent outcomes across late-stage pain programs, including the NGF-inhibitor class.
Placebo responses in osteoarthritis and chronic pain trials are among the largest recorded in clinical medicine, and that complicates nearly every headline about an experimental analgesic. This analysis explains how expectation, trial design, and endpoint selection shape effect sizes — and why the same drug can look brilliant or marginal depending on the comparison group.
When a patient in an NGF-inhibitor trial needs a knee replacement, who decides whether it represents ordinary osteoarthritis progression or a drug-related injury? Independent adjudication committees make that call, and their charter definitions can determine whether a promising analgesic reaches American patients or is shelved.
Tanezumab's Phase III program produced some of the most closely examined safety data in modern pain research. We unpack the efficacy findings, the accelerated osteoarthritis signal, and how advisory committee scrutiny reshaped the drug's trajectory.
Considering a clinical trial or expanded access program for chronic pain? These six questions will help you understand the safety monitoring, eligibility criteria, and regulatory pathways behind investigational therapies before you commit.
From sodium channel blockers to next-generation NGF antibodies, a wave of non-opioid analgesics is moving through late-stage clinical trials. Here's a look at five candidates that could shape the future of pain care in the United States.
Tanezumab was positioned as a landmark non-opioid therapy for chronic osteoarthritis pain, yet it never reached American patients. We examine the clinical evidence, the joint-safety signals, and the regulatory reasoning behind two complete response letters.